Marksans Pharma (MARKSANS)
STALWARTFairStock Score: 32/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹193.25 |
| Market Cap | ₹7,881.88 Cr |
| P/E Ratio | 21.87 |
| ROCE | 20.03% |
| ROE | 19.09% |
| Dividend Yield | 0.46% |
| Profit Growth | 8.26% |
| Debt/Equity | 0.12 |
| Sales Growth | 10.64% |
| Promoter Holding | 43.87% |
| 52-Week Range | ₹155 — ₹270.6 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹28.83 |
Marksans Pharma trades with a P/E ratio of 21.87, ROCE of 20.03%, ROE of 19.09%, profit growth of 8.26%, debt-to-equity of 0.12. The FairStock Score of 32/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer